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Abstract 
Human tissue contents of gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced 
expression in tumor cells were currently examined by a sandwich enzyme immunoassay (EIA) system and a reverse 
transcription-polymerase chain reaction (RT-PCR) method. Gliostatin/PD-ECGF was found to distribute in rather ubiqui- 
tous than specific human tissues and organs, with a relatively high levels in the tissues of digestive system (esophagus and 
rectum), brain, spleen, bladder and lung, but not in gall bladder, aorta, muscle, fat and kidney. Most of examined human 
tumor cell lines showed 4-. or 5-fold higher contents (21.5 _ 3.9 ng/mg protein) than normal tissue contents (4.4_ 1.1 
ng/mg protein) on the average. While gliostatin/PD-ECGF is known to lack a signal sequence, some tumor cells (A431 
and MKN74) appeared to release it into the conditioned medium. Expression of gliostatin/PD-ECGF in epidermoid 
carcinoma cell (A431) and stomach cancer cell (MKN45) was induced by dibutyryl cyclic AMP and phorbol ester, and 
uniquely in MKN45 by hydrocortisone. In particular, this hydrocortisone specifically caused an increase of the apparent 
secretion of MKN74 without its cytotoxic effects, suggesting a possible secretion of gliostatin/PD-ECGF in the restricted 
but not universal cell line. Biological significance on the chemical induction of gliostatin/PD-ECGF in tumor cells and on 
its extracellular secretion are discussed. 
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1. Introduction 
Gliostatin is an acidic protein purified from human 
neurofibroma s glial growth inhibitory factor by 
Abbreviations: PD-ECGF, platelet-derived ndothelial cell 
growth factor; RT-PCR, reverse transcription polymerase chain 
reaction; EIA, enzyme immunoassay; PMSF, phenylmethane- 
sulfonyl fluoride; DTT, dithiothreitol; dbcAMP, dibutyryl-cyclic 
AMP; IBMX, 3-isobutyl-l-rnethylxanthine; TPA, 12-O-tetrade- 
canoylphorbor 13-acetate; DMSO, dimethyl sulfoxide. 
* Corresponding author. Fax: + 81 52 8423316. 
Asai et al [1,2]. Lately, it has been proved that its 
nucleotide sequence is completely identical to that of 
platelet-derived endothelial cell growth factor (PD- 
ECGF) [3], which was purified from human platelets 
[4]. Gliostatin/PD-ECGF is polypeptides of M r = 
100000 with a homodimeric structure comprising 
two 50-kDa subunits, one of which contains 482 
amino acids but not carbohydrate moiety [5]. The 
amino terminus has no signal sequence which is 
necessary for a protein to be secreted out of cells [5]. 
Although both gliostatin and PD-ECGF were purified 
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originally on the basis of [3H]thymidine incorpora- 
tion into C6 cells (rat-astrocytoma) and porcine aortic 
endothelial cells, respectively, very recently glio- 
statin/PD-ECGF is found to involve thymidine phos- 
phorylase (EC 2.4.2.4) activity [6]. Accordingly, the 
decrease or increase in [3H]thymidine incorporation 
by respective factor was a change in appearance. 
However, it has been confirmed that gliostatin/PD- 
ECGF has varied biological actions, besides the enzy- 
matic activity, such as (1) chemotactic activity for 
endothelial cells in vitro [5], (2) angiogenic activity in 
vivo [5], (3) glial differentiative and neurotrophic 
activities including neuronal surviving activity and 
neuritogenic activity in vitro [3,7], and (4) arthrito- 
genic activity in vivo [8]. These functions are not 
fully explained by only its enzyme activity except for 
in vitro angiogenesis [9,10], since some of these 
actions, neurotrophic and arthritogenic a tivities, have 
been found independent of the enzyme activity [5,8]. 
Actual action mechanism of this factor including its 
receptor identification still remains unclear at this 
moment. 
Apart from much controversy on the molecular 
mechanism of its functions, little is known about the 
regulation of gene expression as well as the human 
tissue distribution and content of gliostatin/PD- 
ECGF in detail. And it is also not clear yet whether 
gliostatin/PD-ECGF lacking a signal sequence is 
extra-cellularly secreted in physiological conditions 
or not. Therefore, we investigate the tissue-specific 
distribution of gliostatin/PD-ECGF by sensitive n- 
zyme immunoassay (EIA), and the induction of its 
protein synthesis and gene expression with relevance 
to its secretion, using human tumor cell lines. 
2. Materials and methods 
2.1. Culture of human cell lines 
Human cell lines used in this study are astrocy- 
toma (NAC-1 and NAC-2), glioblastoma (GB-1, 
A172 and T98G), neuroblastoma (GOTO, Nagai, 
TGW and SKN-DZ), neurofibroma (NF-1), prostatic 
adenocarcinoma (PC-3), osteosarcoma (OST), gastric 
cancer (MKN28, MKN45 and MKN74), and epider- 
moid carcinoma (A431). NAC-1, NAC-2, and GB-1 
were established in our laboratory, NF-1 kindly gifted 
from Dr. Ishikawa (Tohoku University Medical 
School), and the other cell lines were obtained from 
the Japanese Cancer Research Resource Bank (JCRB). 
We maintained NAC-1, NAC-2, T98G and SKN-DZ 
in Ham's F-10 medium (F-10 medium, Gibco) con- 
taining 10% fetal bovine serum (FBS, Microbiologi- 
cal Associate), A172 and A431 in Dulbecco's modi- 
fied Eagle's medium (DMEM, Gibco) containing 10% 
FBS, GOTO, Nagai, TGW, MKN28, MKN45, 
MKN74 and OST in RPMI1640 medium containing 
10% FBS, NF-1 in minimum essential medium 
(MEM, Gibco) containing 10% FBS, and PC-3 in 
Ham' s F- 12 medium (F- 12 medium, Gibco) contain- 
ing 10% FBS. All media were routinely supple- 
mented with penicillin (100 units/ml) and strepto- 
mycin (100/zg/ml), and cultures were maintained in
an atmosphere of 5% CO 2 in air and saturated hu- 
midity on 75 cm2-plastic flask (Costar, No. 3275) or 
93-mm diameter dish (NUNC, No. 150350). 
2.2. Enzyme immunoassay (EIA) system for gliostatin 
/ PD-ECGF 
Referring to an EIA system for human-EGF by Joe 
et al. [11], we established an enzyme immunoassay 
system [12]. Gliostatin/PD-ECGF was sandwiched 
between the polyclonal antibody for primary anti- 
body, immobilized on the 96-well immunoplate 
(MaxiSoap, Nunc. No. 446612), and the monoclonal 
anti-gliostatin antibody for the secondary antibody, 
labeled with /3-galactosidase (EC 3.2.1.23) (Boeh- 
ringer-Mannheim). The enzyme reaction at 30°C was 
started by adding 50 ~1 of Buffer A (0.01 M sodium 
phosphate buffer, pH 7.0, containing 0.1 M NaC1, 1 
mM MgC12, 1% bovine serum albumin and 0.1% 
sodium azide) and 50 /zl of 0.3 mM 4-methylumbel- 
liferyl-/3-galactopyranoside (Koch-Light) as substrate, 
and stopped after 1 hour by adding 150 /xl of 0.1 M 
glycine-NaOH buffer (pH 10.3). The fluorescence 
intensity of 4-methylumbelliferone i  the reaction 
mixture was measured with a fluorescence spectro- 
photometer (Hitachi, model No. 650-40) at 360 nm 
excitation and 450 nm emission, against 100 nM of 
4-methylumbelliferone (Wako Pure Chemical) as 
standard. Gliostatin concentration in each test sample 
was measured against a standard curve. The standard 
curve showed a linear line between 1and 100 ng/ml 
(0.1 and 10 ng/well), and the limit of detection was 
0.3 ng/ml (30 pg/well). 
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2.3. Preparation of hunu~n tissue extracts, tumor cell 
extracts and conditioned medium 
Wet weight of each autopsy tissue was measured, 
and 0.02 M Tris buffer containing 10 /~M leupeptin, 
10 /zM pepstatin, 200 /zM phenylmethanesulfonyl 
fluoride (PMSF), 1 rnM dithiothreitol (DTT) was 
added to make 25% homogenates. The homogenate 
was centrifuged at 12000 X g for 30 min, and glio- 
statin contents in the supernatants were measured by 
EIA and expressed as ng/mg protein. Quantification 
of protein contents in the extracts was determined by 
BCA protein assay kit (]Pierce). The conditioned me- 
dia (CM) were collected from the nearly confluent 
cultures of each tumor cell line on 75-cm 2 plastic 
flask. The cell extracts were prepared by sonication 
of scraped cells with a rubber policeman in 2 ml of 
Ca 2+- and MgZ+-free Tyrode's solution (CMF- 
Tyrode) containing protease inhibitors, 10 /xM leu- 
peptin, 10 /xM pepstatin, and 200 /zM PMSF. Glio- 
statin in the conditioned medium or in the extracts of 
the cultured tumor cells was also measured by EIA. 
DehydrogenaseCII-Test Wako), and LDH activity was 
given in Wroblewski Units (WU). LDH activity in 
the identical cell extracts and conditioned medium to 
those for EIA was measured. The rate of dead cell 
(DCR) was calculated by the following equation on 
the basis of LDH activity. 
DCR = [CM-LDH-Med-LDH] × 100 
/[CM-LDH + CE-LDH-Med-LDH] 
CM-LDH, total LDH activity in the conditioned 
medium; Med-LDH, total LDH activity in the fresh 
medium; CE-LDH, total LDH activity in the cell 
extracts. 
2.6. Semi-quantitative analysis of gliostatin/PD- 
ECGF-mRNA by reverse transcription-polymerase 
chain reaction (RT-PCR) 
After drug stimulation for 0, 1, 2, 4, 16, or 24 h, 
RNA fraction was obtained from A431 or MKN45 
cells, which showed a marked gliostatin/PD-ECGF 
2.4. Drug-stimulation of human tumor cells 
Confluent culture of tumor cells was treated with 
dibutyryl-cyclic AMP (dbcAMP, Boehringer 
Mannheim), forskolin (Wako) or 3-isobutyl-l-meth- 
ylxanthine (IBMX, Wako), 12-O-tetradecanoylphor- 
bol 13-acetate (TPA, Sigma), or hydrocortisone 
(Wako) for 20 h. The effect of drugs on 
gliostatin/PD-ECGF expression was examined by 
EIA for gliostatin in the cell extracts and conditioned 
medium of each cell line. For time-dependent experi- 
ments of gliostatin/PD,-ECGF expression, the cells 
were harvested at 0, 1, 2, 4, 16 and 24 h after drug 
stimulation. Secreted gliostatin/PD-ECGF was eval- 
uated with the following equation, 
Secreted gliostatin/PD-ECGF (%) = (the amounts 
of gliostatin/PD-ECGF' in the conditioned medium) 
× 100/[the total amounts of gliostatin/PD-ECGF in 
the conditioned medium and the cell extracts). 
2.5. Measurement of LDH activity 
Lactate dehydrogena,;e (LDH) (EC 1.1.1.27) activ- 
ity was spectrophotometrically measured as an indi- 
cator of cell viability by an LDH-assay kit (Lactate 
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Fig. 1. Gliostatin/PD-ECGF concentrations i  various human 
tissues. Gliostatin/PD-ECGF concentration is expressed as 
ng/mg of protein in the 25% homogenates of each uman tissue. 
Protein contents in the homogenates were separately determined 
by BCA assay. Data indicate the mean value +_ SEM from tripli- 
cate assays, in which the detection limit was 0.3 ng/ml (30 
pg/assay well). 
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induction after addition of dbcAMP, TPA or hydro- 
cortisone, cultured on 93-ram diameter dishes. Total 
RNA was extracted by the acid guanidium-phenol- 
chloroform (AGPC) method escribed by Chomczyn- 
ski (1987) [13]. After washing cultured cells on a dish 
with 2 ml of Ca2+-and Mg=+-free Tyrode's solution, 
1.5 ml of denaturing solution (4 M guanidine isothio- 
cyanate solution containing 25 mM sodium citrate pH 
7.0, 0.5% Sarkosyl, and 0.1 M 2-mercaptoethanol) 
was added and the cell lysate was transferred to a 
tube. 160 /zl of 2 M sodium acetate pH 4.0 was 
added and mixed immediately and thoroughly. The 
cell homogenate was left on ice for 15 min and was 
centrifuged for 15 min at 10000 X g and 4°C, fol- 
lowed by adding 1.6 ml of water-saturated phenol 
and 320 /xl of chloroform/isoamyl alcohol (49:1). 
The supernatant was transferred to another tube, and 
then total RNA was precipitated by adding the equal 
amount of cooled isopropanol to the supernatant. 
After centrifugation for 20 min at 15 700 × g and 
4°C, the precipitate was washed with 70% ethanol, 
and dried up and dissolved with 100 /xl of TE (10 
mM Tris-HC1, pH 8.0, containing 1 mM EDTA). 
Isolated total RNA fraction was measured on the 
basis of absorbance at260 nm. Gliostatin mRNA was 
analyzed by a reverse transcription-polymerase chain 
reaction (RT-PCR) method, in which /3-actin mRNA 
was simultaneously amplified as an internal control. 
PCR products were quantified by a high performance 
capillary electrophoresis (Perkin-Elmer, Model 270A- 
HT). 
2.7. Gene expression of gliostatin / PD-ECGF by 
RT-PCR 
RT-PCR was carried out by the following method 
using RNA PCR Kit (Perkin Elmer). Reagents used 
for RT-PCR are MGC12:25 mM; 10 × PCR buffer: 
100 mM Tris-HC1, pH 8.3 containing 500 mM KCI; 
d-NTP mix (deoxynucleotide triphosphates): contain- 
ing 10 mM dATP, 10 mM dCTP, 10 mM dGTP, and 
10 mM dTTP; RNasin®: 20 U//xl; reverse transcrip- 
tase (Murine Leukemia Virus: MuLV): 50 U//zl; 
Oligo d(T)16 (Sequence: 5'-TTTTTTTTTTTTTTTT- 
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Fig. 2. Gliostatin/PD-ECGF contents in the cell extracts and conditioned medium of cultured human tumor cell lines Gliostatin/PD-ECGF 
concentration is expressed as ng of gl iostatin/PD-ECGF/mg of protein for the samples of cell extracts (A solid bars), and ng/ml  of the 
conditioned medium (hatched bars). The conditioned medium collected and cultured cells in subconfluency in 75 cm 2 plastic flask were 
harvested by a rubber policeman. Data show the mean value of duplicate assays. 
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3'): 50 /zM, and Thermus aquaticus DNA Poly- 
merase (AmpliTaq): 5 U//zl.  
Reverse transcription was conducted in 20 /zl of 
10 mM Tris-HCl (pH 8..3) containing 5 mM MgC12; 
1 mM dATP, 1 mM dCTP, 1 mM dGTP, and 1 mM 
dTFP; 1 U//x l  RNasin ®, 2.5 U//x l  Reverse Tran- 
scriptase and 2.5 /zM Oligo d(T)16. The enzyme 
reaction mixture was prepared in a 0.5-ml tube, and 
cDNAs were synthesized at 42°C for 30 min. Then, 
mRNA-cDNA chains were denatured and the reverse 
transcriptase activity was arrested by heating up to 
99°C for 5 rain. 
PCR was successively carried out in 100 /xl of 10 
mM Tris-HC1 (pH 8.3) containing 1 mM dATP, 1 
mM dCTP, 1 mM dGTP, 1 mM dTTP, 2 mM 
MgCI2; 10% DMSO (Dimethyl sulfoxide) and 0.025 
U//xl  AmpliTaq. After adding the upstream primer 
(5 ' -GTGGAGGGGCTGTCCGCTCTGGTGGTG- 
GAC-3') and downstream primer (5'-CAGCATC- 
CGCTCGAAGCGGCCAAGGGCCGA-3') for glio- 
statin/PD-ECGF, PCR was carried out for the initial 
6 cycles. Further PCR 'was continued for another 24 
cycles followed by adding the upstream primer (5'- 
TACATGGCTGGG-GTGTTGAA-3') and down- 
stream primer (5'-AAGAGAGGCATCCTCACCCT- 
3') for/3-actin. Estimated nucleotide-numbers of PCR 
products were 372 bp for gliostatin/PD-ECGF and 
218 bp for/3-actin, respectively. PCR was performed 
under the following conditions, denaturing step: 95°C 
for 30 s annealing step: 58°C for 30 s, and extension 
step: 72°C for 60 s. 1 /xl of PCR products was 
diluted with 19 /zl of distilled water and analyzed 
using high performance capillary electrophoresis. 
PCR products of gliostatin/PD-ECGF and /3-actin 
were quantitatively analyzed by integrating each peak 
area with respect o the absorbance at 260 nm, and 
the relative amount of gliostatin/PD-ECGF-mRNA 
for/3-actin mRNA was measured. 
from each tumor cell was run on agarose gels and 
transferred to nylon filter membranes. The mem- 
branes were hybridized with 8300 Bq of [7- 
32p]ATP-labeled probes for glucocorticoid receptor 
or human /3-actin (300 bp). The hybridization was 
performed in a solution containing 50% formamide, 
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2.8. Identification of glucocorticoid receptor 
Oligonucleotide probe of human glucocorticoid re- 
ceptor, a 40-base single stranded synthetic oligo- 
nucleotide (47.5% GC contents, Oncogene Science), 
was used for Northern blot analysis. The sequence is
of the antisense orientation and is derived from se- 
quences corresponding to the amino terminus of hu- 
man glucocorticoid receptor [14]. 20 /xg of RNA 
Fig. 3. Drug-induction f gliostatin/PD-ECGF protein in four 
representative tumor cell lines. Four representative tumor cell 
lines (A431, GOTO, MKN45, and MKN74) showing a high 
concentration of intra-cellular gliostatin/PD-ECGF (as shown in 
Fig. 2) were used for the drug-induction experiments. The stimu- 
lated cells for 20 h by the indicated concentrations f dbcAMP 
(A), TPA (B), and hydrocortisone (C) were harvested and sub- 
jected to the EIA after emoval of the conditioned medium also 
for the assay. Induction rates were expressed as% increase of 
control level in each cell line described in Table 1. Data indicate 
the mean value of duplicate experiments in sister cultures. 
76 K. Matsukawa et al. / Biochimica et Biophysica Acta 1314 (1996) 71-82 
5 × saline-sodium citrate (SSC), 1.5 × Denhardt's so- 
lution, 0.1% sodium dodecyl sulfate (SDS), 10% 
dextran sulfate, and 0.1 mg/ml  of salmon sperm 
DNA for 18 h at 42°C. The filters were washed twice 
(2 × 15 min) in 2 × SSC/0.1% SDS buffer at room 
temperature, and once for 30 min in 2 X SSC/0.1% 
SDS at 65°C. After removal of the last probe, filters 
were rehybridized to a labeled oligonucleotide probe 
for human fl-actin. Separately, human glucocorticoid 
receptor in the cell extracts of each tumor cell line 
was visualized by a conventional Western blot method 
with a rabbit polyclonal antibody against human glu- 
cocorticoid receptor (Santa Cruz Biotechnology). 
shown in Fig. 1, relatively high contents of glio- 
statin/PD-ECGF were detected in tissues of diges- 
tive system, brain, liver, and pancreas. Spleen and 
bladder also showed fairly high concentrations. Al- 
though thyroid and lung had a detectable but not 
much gliostatin/PD-ECGF, there was no detectable 
gliostatin/PD-ECGF in gall bladder, kidney, fat, 
muscle and aorta. The finding that cerebrum and 
cerebellum were fairly rich in gliostatin/PD-ECGF 
may reflect its gliotropic and neurotrophic actions. 
3.2. Gliostatin-contents in varied human tumor cell 
lines and its secretion 
3. Results 
3.1. Tissue distribution of gliostatin / PD-ECGF 
Gliostatin/PD-ECGF contents in a variety of hu- 
man tissues were examined by EIA (Fig. 1). As 
Gliostatin was screened in the cultured cell ex- 
tracts and the conditioned media from a number of 
human tumor cell lines (Fig. 2); neurofibroma cells 
(NF-1), osteosarcoma cells (OST), epidermoid carci- 
noma cells (A431), prostatic adenocarcinoma cells 
(PC-3), gastric cancer cells (MKN28, MKN45, and 
MKN74), and neural tumor cells (SKN-DZ, TGW, 
A431 
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Fig. 4. Time-dependent i duction of gliostatin/PD-ECGF protein in A431 and MKN45 cells. Two kinds of human tumor cell lines, A431 
and MKN45, which display a marked induction to dbcAMP, TPA, or hydrocortisone in Fig. 3, were used for the time-dependent 
experiments. Both cell lines were stimulated by either 5 mM dbcAMP, 1 nM TPA, or 10 -6 M hydrocortisone. At the indicated 
time-periods, cells were harvested by a rubber policeman and its homogenates were subjected to the EIA. Induction rates were expressed 
as % increase of control level in each cell line described in Table 1. Data indicate the mean value of duplicate experiments in sister 
cultures. 
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Nagai, GOTO, T98G, GB-1, NAC-1 and NAC-2). A 
high concentration of gliostatin/PD-ECGF was de- 
tected in the extracts from A431, MKN74, GOTO 
and MKN45 ceils. Most of examined human tumor 
cell lines showed 4- or 5-fold higher contents (21.5 _ 
3.9 ng/mg protein) than normal tissue contents (4.4 
+ 1.1 ng/mg protein) on the average. While major- 
ity of the conditioned media showed no detectable 
gliostatin/PD-ECGF, there was, exceptionally, a cer- 
tain level of gliostatin/PD-ECGF in the conditioned 
media from A431 and MKN45 cells, indicating a 
possibility of the extra-cellular secretion. Therefore, 
we have tried to examine (1) changes in levels of 
gliostatin/PD-ECGF expression and (2) changes in 
the extra-cellular secretion of gliostatin/PD-ECGF 
by plausible drugs to modulate cell growth and dif- 
ferentiation. 
3.3. Effects of carious drug-stimulations ongliostatin 
/ PD-ECGF production 
We chose two groups of human cell lines, one 
possibly releasing gliostatin/PD-ECGF (A431 and 
MKN74 cells) and another not (GOTO and MKN45 
cells), among potent producer  cells of 
gliostatin/PD-ECGF. Both groups of cells were 
stimulated for 20 h by dbcAMP, TPA or hydrocorti- 
sone to examine the effects on gliostatin/PD-ECGF- 
production measured by EIA (Fig. 3). Gliostatin in 
A431 was induced ose-dependently by dbcAMP and 
TPA, and in MKN45 was also induced by dbcAMP, 
TPA and hydrocortisone. Thus, it was indicated that 
A-kinase and C-kinase in A431, and steroid binding 
protein besides former two in MKN45 were involved 
in the regulation pathway of gliostatin/PD-ECGF 
expression. But GOTO and MKN74 showed no in- 
duction by any drug stimulation. To further examine 
the participation of cyclic AMP in gliostatin/PD- 
ECGF-production i  A431, forskolin, an activator of 
adenylate cyclase, or IBMX, an inhibitor of phospho- 
diesterase, was used. In support of above results, the 
intracellular gliostatin/PD-ECGF contents of A431 
elevated about 2.1 times by 10/zM forskolin and 1.2 
times by 0.5 mM IBMX (data not shown). Sepa- 
rately, the changes in :morphological feature by db- 
cAMP (5 mM), TPA (10 nM) or hydrocortisone 
(10-6M) were observed on four cell lines. Only 
A431 displayed enlarged cellular bodies by dbcAMP, 
indicating the induction of morphological differentia- 
tion (data not shown). No remarkable morphological 
change or cytotoxic effect was detected in other 
drugs or other cell lines. 
3.4. Time-course of gliostatin / PD-ECGF expression 
after the drug stimulation 
Time-dependent changes in gliostatin/PD-ECGF- 
induction at the protein level were monitored by EIA 
after drug stimulation at the doses eliciting a promi- 
nent induction in the penultimate dose-dependent x-
periments, 1 mM dbcAMP or 1 nM TPA for A431 
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Fig. 5. The precision of RT-PCR method to examine the gene 
expression of gliostatin/PD-ECGF. (A) 1 p,g of RNA fractions 
isolated from A431 cells was used for RT-PCR to determine the 
appropriate numbers of amplification cycles for the expression of 
gliostatin/PD-ECGF mRNA and /3-actin mRNA as an internal 
control. This experiment demonstrated that the best PCR-cycle 
number was obtained between 27 and 30 cycles for 
gliostatin/PD-ECGF, and between 21 and 24 cycles for fl-actin. 
(B) Dose-dependent expression of both mRNAs was confirmed 
in RT-PCR using varied amounts of RNA fractions. All PCR- 
products from both experiments (A and B) were subjected to a 
semi-quantification by a capillary electrophoresis. Vertical axis 
indicates the amounts of PCR products expressed as each peak 
area of A26on m ( txV. s) obtained from elution profiles of capillary 
electrophoresis. 
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cells, and 1 mM dbcAMP, 1 nM TPA, or 1 /~M 
hydrocortisone for MKN45 cells. Gliostatin contents 
in each cell extract were measured at 0, 1, 2, 4, 16, 
24 h after drug stimulation. Gliostatin in A431 cells 
was maximally induced at 16 h by dbcAMP or TPA, 
and in MKN45 by dbcAMP or TPA was time-depen- 
dently induced but maximally at 2 h by hydrocorti- 
sone (Fig. 4). 
3.5. Gene-expression of gliostatin / PD-ECGF and 
glucocorticoid receptor 
Furthermore, changes in expression of 
gliostatin/PD-ECGF mRNA were examined in the 
experiment of time-course using RT-PCR method 
(Fig. 5). As a preliminary experiment, 1 /zg of total 
RNA isolated from A431 was amplified by RT-PCR 
and the amount of PCR products for gliostatin/PD- 
ECGF or/3-actin was measured at every 3-cycles by 
high performance capillary electrophoresis. In the 
amplification curve against cycle number, the 
amplification rate of gliostatin/PD-ECGF mRNA be- 
tween 27 and 30 cycles was parallel to that of/3-actin 
between 21 and 24 cycles (Fig. 5A). Therefore, the 
primers for/3-actin were added 6 cycles later than the 
primers for gliostatin/PD-ECGF, and PCR was ter- 
minated at 30 cycles for gliostatin/PD-ECGF and 24 
cycles for /3-actin. In this PCR method, both of the 
amplification curves of gliostatin/PD-ECGF and /3- 
actin against amounts of added total RNA (0 to 1.0 
/zg/tube) showed a straight line (Fig. 5B). The accu- 
racy of PCR products (372 bp) from the mRNA 
fractions of both 2A431 and MKN 45 cells was 
confirmed by the restriction map of NcoI digests 
comprising two enzymatic fragments (145 bp and 
227 bp) (Fig. 6) as well as by their direct sequence 
analyses (data not shown). Thus, it was confirmed 
that this RT-PCR method employing capillary elec- 
trophoresis is applicable for the semi-quantitative 
analysis of gliostatin/PD-ECGF mRNA. Induction 
of gliostatin/PD-ECGF mRNA in A431 started by 4 
h after dbcAMP stimulation and by 16 h after TPA 
stimulation (Fig. 7), and in MKN45 started at earliest 
2 h after the stimulation of dbcAMP, TPA or hydro- 
cortisone (Fig. 7). The dbcAMP-dependent i duction 
in A431, showing a lag phase for several hours after 
the stimulation and a gradual increment, was not 
suppressed by 10 /zg/ml of cycloheximide (data not 
a 
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Fig. 6. The acuracy of PCR products from A431 and MKN45 
cells. (a) A typical elution profile of RT-PCR products from 
A431 cells on high performance capillary elelctrophoresis. Verti- 
cal axis indicates the amounts ofPCR products expressed aseach 
peak area of Aa6on m (/zV. s) obtained from elution profiles of 
capillary electrophoresis. Hatched peak indicates the RT-PCR 
product. (b) An elution profile of NcoI-digests of RT-PCR 
product from A431 cells. Plastared peaks with black indicate 
NcoI-restriction fragments. (c)An elution profile of the mixture 
of NcoI-digests of RT-PCR products from MKN45 cells and 
molecular size markers (Gibco BRL). Figures on peaks indicate 
the molecular size (bp) of each standard DNAs. (d) TR-PCR 
products from MKN45 cells visualized on ethidium bromide 
agarose gel. Lane 1 is a molecular size marker of ~bx174/HaelII 
digests. Lane 2 is an RT-PCR product from MKN45 cells. Lane 3 
is an NcoI-digest of the product plausibly comprising of two 
fragments (145 bp and 227 bp). Vague bands at the bottom of 
lane 2 and 3 indicate the primers used for PCR. (el Mol wt. 
estimation ftwo fragments in NcoI-digests ofRT-PCR products 
from MKN45 cells. Open circles indicate corresponding molecu- 
lar size markers. Arrows indicate the estimated molecular size of 
NcoI-restriction fragments (145 bp and 227 bp) and intact RT- 
PCR product (372 bp). 
shown). In short, A431 and MKN45 were definitely 
different each other in the initiation time for the 
expression of gliostatin/PD-ECGF mRNA, suggest- 
ing that the intra-cellular mechanism of 
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Fig. 7. Time-dependent expression of gliostatin/PD-ECGF mRNA in A431 and MKN45 cells. A431 and MKN45 cells were stimulated 
by either 5 mM dbcAMP, 1 nM TPA, or 10-6M hydrocortisone. At the indicated time-periods, RNA fractions were prepared from each 
cells under the methods precisely described in the text, and subjected to the RT-PCR. Induction rates were expressed as % increase of 
control expression level in each cell line on the basis of relative amounts of gliostatin/PD-ECGF mRNA for fl-actin mRNA. Data 
indicate the mean value of duplicate xperiments in sister cultures. 
Table 1 
Effect of drugs on gliostatin/PD-ECGF contents measured by EIA in the cell extracts and the conditioned medium 
A431 MKN74 
CE ng/  CM ng/  GR % DCR % CE ng/  CM ng/  CR % DCR % 
flask flask flask flask 
Control 
dbcAMP: 
TPA: 
Hydrocortisone: 
98 3.8 3.7 2.3 241 9.4 3.8 12.7 
0.5 mM 963 3.2 0.3 0.9 290 5.8 2.0 12.9 
1 mM 603 11.2 1.8 2.1 271 7.6 2.7 11.8 
5 mM 569 4.5 0.8 1.6 265 7.0 2.6 12.7 
1 nM 306 9.3 2.9 0.8 262 4.8 1.8 23.0 
5 nM 673 7.4 1.1 0.8 387 7.7 2.0 8.4 
10 nM 766 8.0 1.0 2.8 152 3.8 2.4 12.9 
0.01 mM 86 11.5 11.8 19.6 324 26.0 7.4 10.8 
0.1 mM 105 10.7 9.2 12.7 116 23.0 16.6 12.1 
1 mM 85 6.9 7.5 15.6 165 20.0 10.8 9.1 
19 mM 95 3.0 3.1 8.9 282 22.0 7.2 9.2 
Subconfluent cultures of both A431 and MKN74 cells in 75 cm2-plastic flask were stimulated for 20 hours by the indicated 
concentrations of dbcAMP, TPA, and hydrocortisone. Gliostatin/PD-ECGF contents are expressed as the total amounts in a culture flask 
for the cell extracts (CE) or in the conditioned medium (CM). LDH activity is expressed as the total activity in a culture flask for the cell 
extracts (CE) or in the conditioned medium (CM). DCR: the percentage of dead cell number estimated by the LDH activity, using the 
equation described in the text:. Data indicate the mean value of duplicate xperiments in sister cultures. 
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gliostatin/PD-ECGF expression is dependent of cell 
differences. 
To elucidate the change in glucocorticoid receptor 
expression, Northern blot analysis using an oligo- 
nucleotide probe of human glucocorticoid receptor 
was carried out for four tumor cell lines. There was 
neither change in its constitutional expression, but a 
trace band on Northern blots, among four cell lines, 
nor detectable induction by any drug stimulation 
(data not shown). The similar result was also evident 
by Western blot analysis (data not shown). 
3.6. Extra-cellular secretion of gliostatin / PD-ECGF 
We examined the change in secretion of glio- 
statin/PD-ECGF from four cell lines by drug stimu- 
lations. A431 and MKN74 cells, which released cer- 
tain levels of gliostatin/PD-ECGF in their condi- 
tioned medium without stimulation as shown in Fig. 
2, were accelerated to secrete by only hydrocortisone 
but not by dbcAMP or TPA (Table 1). However, the 
increased secretion by hydrocortisone in A431 cells 
was accompanying the elevation of LDH activity, but 
that in MKN74 cells was not in the conditioned 
medium. The results suggest hat glucocorticoid is 
specifically triggering a mechanism to augment he 
extracellular secretion of gliostatin/PD-ECGF in 
MKN74, a gastric cancer cell line. 
4. Discussion 
In our current study using a sandwich-type EIA 
system, gliostatin/PD-ECGF was found to distribute 
in rather general than specific human tissues and 
organs. It was detected at a relatively high level in 
the tissues of digestive system (esophagus and rec- 
tum), brain, spleen, bladder and lung, but not in gall 
blabber, aorta, muscle, fat and kidney. On the basis 
of thymidine phosphorylase (TdR Pase) activity, 
Yoshimura et al. previously reported tissue distribu- 
tions of the activity that lymph nodes, spleen, liver, 
and lung showed a high activity, and colon, stomach, 
heart, kidney and small intestine did a lower enzyme 
activity, but not in muscle at all [15]. Both EIA and 
enzymatic assay methods imilarly revealed a ubiqui- 
tous distribution of gliostatin/PD-ECGF in human 
tissues. It is of interest hat most of examined tumor 
cell lines, regardless of their origins, showed three- or 
four-fold higher contents than normal human tissues, 
and that some tumor cells appeared to release a 
significant amounts of gliostatin/PD-ECGF. Consid- 
ering biological actions of gliostatin/PD-ECGF as 
angiogenic factor and thymidine phosphorylase, it is 
speculated that gliostatin/PD-ECGF might partici- 
pate in angiogenesis for tumor mass expansion, or 
reflect an aberrant intra-cellular metabolism of pyrim- 
idine nucleotides closely related to malignant umor 
growth. 
To investigate the regulatory mechanism of glio- 
statin/PD-ECGF gene expression, 4 kinds of tumor 
cell lines (A431, MKN45, MKN74 and GOTO) were 
stimulated by the drugs such as dbcAMP, TPA, and 
hydrocortisone. Our data showed that gliostatin/PD- 
ECGF synthesis was induced by dbc AMP or TPA in 
both A431 and MKN45 cells at the protein and 
mRNA levels. TPA has been found to augment 
thymidien phosphorylase activity of lymphoma cell 
line, U-937 [16], and A431 unlikely due to the phos- 
phorylation by protein kinase C [17]. Considering 
these findings, the expression of gliostatin/PD-ECGF 
might be regulated by transcription level. MKN45 
uniquely displayed a prominent induction at both 
levels by hydrocortisone. It should be, however, noted 
that there was no detectable difference in glucocorti- 
coid receptor at either its protein or mRNA level 
among these four cell lines (data not shown). 
Hagiwara et al. previously reported that by cloning 
human PD-ECGF gene and sequencing its flanking 
region, 1.4-kb 5'-flanking region, possibly carrying 
promoter activity, lacked plausible consensus se- 
quences such as cAMP-response element (CRE), 
TPA-response lement (TRE), and glucocorticoid-re- 
sponse element (GRE), except for SP1 site rich in G 
and C [18]. However, there remains a possibility that 
these consensus equences, where CREB, AP-1 or 
steroid itself is capable of binding to regulate the 
gliostatin/PD-ECGF gene expression, may exist as 
an enhancer at a more up- or down-stream than 1.4 
kb 5'-flanking region. The dbcAMP-induced expres- 
sion of gliostatin/PD-ECGF mRNA in A431 was not 
suppressed by cycloheximide, indicating that this in- 
duction may not be mediated via newly synthesized 
transcription regulatory factors. Interestingly, Eda et 
al. reported that TNFa, IL-1 a, and INFy enhanced 
the enzyme activity of TdR Pase in WiDr cells (colon 
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cancer cell line) [19], and our study also confirmed 
the induction of gliostatin/PD-ECGF mRNA by 
TNFol in A431 cells (data not shown). These cy- 
tokine-dependent i duction implies a mediation of 
certain gene regulatory proteins such as NFKB and 
IRF-1 to regulate the expression. Taken together, 
these data suggest hat molecular mechanisms of 
gliostatin/PD-ECGF gene expression are varied in 
difference of tested cell lines and stimulants. 
It has been known that gliostatin/PD-ECGF lacks 
the signal sequence for a protein secretion, but its 
receptors remains yet unexplicated so far. Fibroblast 
growth factor [20,21] and interleukin 1[22,23], never- 
theless lacking signal peptides, are speculated to be 
secreted out of each producer cell, and found to act 
exogenously on target cells through their cell surface 
receptors [24-30]. In fact, we could currently detect a
certain level of gliostatin/PD-ECGF in the condi- 
tioned medium from A431 and MKN74 cells. Then, 
to define whether or not gliostatin/PD-ECGF is actu- 
ally secreted, we examined changes of 
gliostatin/PD-ECGF levels in the conditioned 
medium of A431 and MKN74 cells after the stimula- 
tion by dbcAMP, TPA or hydrocortisone, under mon- 
itoring LDH activity as an indicator of cell damages. 
Hydrocortisone promoted the secretion from MKN74 
without the induction cf gliostatin/PD-ECGF, but 
not from A431. The current data support the possibil- 
ity that gliostatin/PD--ECGF might be physio- 
logically secreted from only the specified, but not all, 
cell line such as MKN74. Supportingly, it has been 
recently reported that TNFo~ or ILl-/3 brought out 
remarkable secretions of gliostatin/PD-ECGF with- 
out the decline of cell viability from non-tumor cells 
such as synovial ining ,-ells and mesenchymal cells 
[31]. In further support of this possibility, Usuki et al. 
has reported that intracellular PD-ECGF was linked 
with nucleotide, ATP, and nucleotidylation of PD- 
ECGF might be of importance in the secretion of 
PD-ECGF from cells in a signal sequence-indepen- 
dent manner [ 17]. Whatever the releasing mechanism, 
gliostatin/PD-ECGF stored in cytosol will be not 
only released coincidentally with cell damage (cell 
death) but also physiologically secreted from certain 
cells, and may act as angiogenic factor and chemo- 
attractant on their adjacent target cells. It would be a 
general scheme of tumor growth that, when certain 
numbers of cells in tumor mass fall into cell death, 
gliostatin/PD-ECGF will be released out of dead 
cells and induce angiogenesis to supply enough nutri- 
ents for further neoplastic proliferation of remaining 
tumor cells. From clinical view-points, it is of impor- 
tance to develop a specific inhibitor to suppress the 
production or biological functions of gliostatin/PD- 
ECGF at tumor loci. 
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